Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome (original) (raw)

Abstract

Probiotic bacteria exhibit a variety of properties, which are unique to a particular strain. _Lactobacillus acidophilus_-SDC 2012, 2013 are new strains isolated from Korean infants’ feces. The potential utility of _Lactobacillus acidophilus_-SDC 2012, 2013 in irritable bowel syndrome (IBS) was studied. Forty IBS patients were randomized into a placebo (n = 20) and probiotics group (n = 20). Four weeks of treatment with _L. acidophilus-_SDC 2012, 2013 was associated with a reduced score for abdominal pain or discomfort compared to the baseline (P = 0.011). The percent reduction in abdominal pain or discomfort exceeded the placebo scores by more than 20% (23.8 and 0.2% for probiotics and placebo, respectively, P = 0.003). There was a significant difference in the proportion of responders between the probiotics and placebo groups (P = 0.011). There was no drop out or adverse events for either group during the study period. _Lactobacillus acidophilus_-SDC 2012, 2013 appeared to have a beneficial effect in patients with IBS. Further studies are warranted.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Schrezenmeir J, de Vrese M (2001) Probiotics, prebiotics, and synbiotics–approaching a definition. Am J Clin Nutr 73:361S–364S
    PubMed CAS Google Scholar
  2. Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A, Walker WA, Fedorak RN, Camilleri M (2006) Recommendations for probiotic use. J Clin Gastroenterol 40:275–278
    Article PubMed Google Scholar
  3. Quigley EM, Flourie B (2007) Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 19:166–172
    Article PubMed CAS Google Scholar
  4. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95:1231–1238
    Article PubMed CAS Google Scholar
  5. Niedzielin K, Kordecki H, Birkenfeld B (2001) A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 13:1143–1147
    Article PubMed CAS Google Scholar
  6. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17:895–904
    Article PubMed CAS Google Scholar
  7. O’Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM (2005) Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128:541–551
    Article PubMed Google Scholar
  8. Rhee PL (2006) Definition and epidemiology of irritable bowel syndrome. Korean J Gastroenterol 47:94–100
    PubMed Google Scholar
  9. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC (2006) Functional bowel disorders. Gastroenterology 130:1480–1491
    Article PubMed Google Scholar
  10. Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO (1992) Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 33:818–824
    Article PubMed CAS Google Scholar
  11. Irvine EJ, Whitehead WE, Chey WD, Matsueda K, Shaw M, Talley NJ, Veldhuyzen van Zanten SJ (2006) Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 130:1538–1551
    Article PubMed Google Scholar
  12. Wilson A, Longstreth GF, Knight K, Wong J, Wade S, Chiou CF, Barghout V, Frech F, Ofman JJ (2004) Quality of life in managed care patients with irritable bowel syndrome. Manag Care Interface 17:24–28, 34
    Google Scholar
  13. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ (2003) Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 98:600–607
    Article PubMed Google Scholar
  14. Camilleri M (2006) Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 40:264–269
    Article PubMed Google Scholar
  15. Ringel-Kulka T, Ringel Y (2007) Probiotics in irritable bowel syndrome: has the time arrived? Gastroenterology 132:813–816; discussion 816
    Article PubMed Google Scholar
  16. Riordan SM, Kim R (2006) Bacterial overgrowth as a cause of irritable bowel syndrome. Curr Opin Gastroenterol 22:669–673
    Article PubMed Google Scholar
  17. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I (2006) A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333
    Article PubMed CAS Google Scholar
  18. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R (2005) A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22:387–394
    Article PubMed CAS Google Scholar
  19. Camilleri M (2006) Is there a role for probiotics in irritable bowel syndrome? Dig Liver Dis 38(Suppl 2):S266–S269
    Article PubMed Google Scholar

Download references

Acknowledgement

Financial support: The authors were supported, in part, by grants from the Seoul Research and Business Development Program (No. 10582).

Author information

Authors and Affiliations

  1. Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
    Dong Hyun Sinn, Hoi Jin Kim, Jun Haeng Lee, Hee Jung Son, Dong Kyung Chang, Young-Ho Kim, Jae J. Kim, Jong Chul Rhee & Poong-Lyul Rhee
  2. Healthcare System, Gangnam Center, Seoul National University Hospital, Seoul, Korea
    Ji Hyun Song
  3. Division of Gastroenterology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, Korea
    Poong-Lyul Rhee

Authors

  1. Dong Hyun Sinn
    You can also search for this author inPubMed Google Scholar
  2. Ji Hyun Song
    You can also search for this author inPubMed Google Scholar
  3. Hoi Jin Kim
    You can also search for this author inPubMed Google Scholar
  4. Jun Haeng Lee
    You can also search for this author inPubMed Google Scholar
  5. Hee Jung Son
    You can also search for this author inPubMed Google Scholar
  6. Dong Kyung Chang
    You can also search for this author inPubMed Google Scholar
  7. Young-Ho Kim
    You can also search for this author inPubMed Google Scholar
  8. Jae J. Kim
    You can also search for this author inPubMed Google Scholar
  9. Jong Chul Rhee
    You can also search for this author inPubMed Google Scholar
  10. Poong-Lyul Rhee
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toPoong-Lyul Rhee.

Rights and permissions

About this article

Cite this article

Sinn, D.H., Song, J.H., Kim, H.J. et al. Therapeutic Effect of _Lactobacillus acidophilus_-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome.Dig Dis Sci 53, 2714–2718 (2008). https://doi.org/10.1007/s10620-007-0196-4

Download citation

Keywords